Nandita S. Scott

Dr. Nandita S. Scott

1. Department of Medicine, Division of Cardiology, Massachusetts General Hospital, Boston, MA 02114, USA
+1

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
14 February 2023 in Circulation
Verified
Journal Article
Closed access
LCLeslie Cho
Leslie Cho
AKAndrew M. Kaunitz
Andrew M. Kaunitz
SFStephanie S. Faubion
Stephanie S. Faubion
SHSharonne N. Hayes
Sharonne N. Hayes
ELEmily S. Lau
Emily S. Lau
FCfor the ACC CVD in Women Committee
for the ACC CVD in Women Committee
Menopausal hormone therapy (HT) was widely used in the past, but with the publication of seminal primary and secondary prevention trials that reported an excess cardiovascular risk with combined estrogen-progestin, HT use declined significantly. However, over the past 20 years, much has been learned about the relationship between the timing of HT use with respect to age and time since menopause, HT route of administration, and cardiovascular disease risk. Four leading medical societies recommend HT for the treatment of menopausal women with bothersome menopausal symptoms. In this context, this review, led by the American College of Cardiology Cardiolovascular Disease in Women Committee, along with leading gynecologists, women’s health internists, and endocrinologists, aims to provide guidance on HT use, including the selection of patients and HT formulation with a focus on caring for symptomatic women with cardiovascular disease risk.

26 August 2022 in JACC: Advances
Verified
Journal Article
Open access
ASAmy A. Sarma
Amy A. Sarma
NANiti R. Aggarwal
Niti R. Aggarwal
JBJoan E. Briller
Joan E. Briller
MDMelinda Davis
Melinda Davis
KEKatherine E. Economy
Katherine E. Economy
Nandita S. ScottNandita S. Scott
Nandita S. Scott
Cardiac biomarkers are widely used in the nonpregnant population when acute cardiovascular (CV) pathology is suspected; however, the behavior of these biomarkers in the context of pregnancy is less well understood. Pregnant individuals often have symptoms that mimic those of cardiac dysfunction, and complications of pregnancy may include CV disease. This paper will summarize our current knowledge on the use of cardiac biomarkers in pregnancy and provide suggestions on how to use these tools in clinical practice based on the available evidence. Natriuretic peptides and troponin should not be measured routinely in uncomplicated pregnancy, where values should remain low as in the nonpregnant population. In the context of pre-existing or suspected CV disease, these biomarkers retain their negative predictive value. Elevations of both natriuretic peptides and troponin may occur without clear clinical significance in the immediate postpartum period. Elevations of these markers should always prompt further investigation into possible CV pathology.

17 August 2020 in Circulation
Verified
Journal Article
Closed access
PDF file
MHMichael C. Honigberg
Michael C. Honigberg
MCMark Chaffin
Mark Chaffin
KAKrishna Aragam
Krishna Aragam
DBDeepak L Bhatt
Deepak L Bhatt
MWMalissa J. Wood
Malissa J. Wood
PNPradeep Natarajan
Pradeep Natarajan

1 June 2024 in Hypertension
Verified
Journal Article
Open access
MHMichael C. Honigberg
Michael C. Honigberg
KEKatherine E. Economy
Katherine E. Economy
MPMaria A. Pabón
Maria A. Pabón
XWXiaowen Wang
Xiaowen Wang
CCClaire Castro
Claire Castro
MCMarcelo F. Di Carli
Marcelo F. Di Carli
BACKGROUND: Preeclampsia is a pregnancy-specific hypertensive disorder associated with an imbalance in circulating proangiogenic and antiangiogenic proteins. Preclinical evidence implicates microvascular dysfunction as a potential mediator of preeclampsia-associated cardiovascular risk. METHODS: Women with singleton pregnancies complicated by severe antepartum-onset preeclampsia and a comparator group with normotensive deliveries underwent cardiac positron emission tomography within 4 weeks of delivery. A control group of premenopausal, nonpostpartum women was also included. Myocardial flow reserve, myocardial blood flow, and coronary vascular resistance were compared across groups. sFlt-1 (soluble fms-like tyrosine kinase receptor-1) and PlGF (placental growth factor) were measured at imaging. RESULTS: The primary cohort included 19 women with severe preeclampsia (imaged at a mean of 15.3 days postpartum), 5 with normotensive pregnancy (mean, 14.4 days postpartum), and 13 nonpostpartum female controls. Preeclampsia was associated with lower myocardial flow reserve (β, −0.67 [95% CI, −1.21 to −0.13]; P =0.016), lower stress myocardial blood flow (β, −0.68 [95% CI, −1.07 to −0.29] mL/min per g; P =0.001), and higher stress coronary vascular resistance (β, +12.4 [95% CI, 6.0 to 18.7] mm Hg/mL per min/g; P =0.001) versus nonpostpartum controls. Myocardial flow reserve and coronary vascular resistance after normotensive pregnancy were intermediate between preeclamptic and nonpostpartum groups. Following preeclampsia, myocardial flow reserve was positively associated with time following delivery ( P =0.008). The sFlt-1/PlGF ratio strongly correlated with rest myocardial blood flow ( r =0.71; P <0.001), independent of hemodynamics. CONCLUSIONS: In this exploratory cross-sectional study, we observed reduced coronary microvascular function in the early postpartum period following preeclampsia, suggesting that systemic microvascular dysfunction in preeclampsia involves coronary microcirculation. Further research is needed to establish interventions to mitigate the risk of preeclampsia-associated cardiovascular disease.

18 March 2024 in JACC: Advances
Verified
Journal Article
Open access
ELEmily S. Lau
Emily S. Lau
NANiti R. Aggarwal
Niti R. Aggarwal
JBJoan E. Briller
Joan E. Briller
DCDaniela R. Crousillat
Daniela R. Crousillat
KEKatherine E. Economy
Katherine E. Economy
Nandita S. ScottNandita S. Scott
Nandita S. Scott
Maternal mortality is a major public health crisis in the United States. Cardiovascular disease (CVD) is a leading cause of maternal mortality and morbidity. Labor and delivery is a vulnerable time for pregnant individuals with CVD but there is significant heterogeneity in the management of labor and delivery in high-risk patients due in part to paucity of high-quality randomized data. The authors have convened a multidisciplinary panel of cardio-obstetrics experts including cardiologists, obstetricians and maternal fetal medicine physicians, critical care physicians, and anesthesiologists to provide a practical approach to the management of labor and delivery in high-risk individuals with CVD. This expert panel will review key elements of management from mode, timing, and location of delivery to use of invasive monitoring, cardiac devices, and mechanical circulatory support.

Verified
Journal Article
Open access
PDF file
JCJulie Coursen
Julie Coursen
CSCatherine E. Simpson
Catherine E. Simpson
MMMonica Mukherjee
Monica Mukherjee
AVArthur J. Vaught
Arthur J. Vaught
SKShelby Kutty
Shelby Kutty
GSGarima Sharma
Garima Sharma
Pulmonary arterial hypertension (PAH) is a vasoconstrictive disease of the distal pulmonary vasculature resulting in adverse right heart remodeling. Pregnancy in PAH patients is associated with high maternal morbidity and mortality as well as neonatal and fetal complications. Pregnancy-associated changes in the cardiovascular, pulmonary, hormonal, and thrombotic systems challenge the complex PAH physiology. Due to the high risks, patients with PAH are currently counseled against pregnancy based on international consensus guidelines, but there are promising signs of improving outcomes, particularly for patients with mild disease. For patients who become pregnant, multidisciplinary care at a PAH specialist center is needed for peripartum monitoring, medication management, delivery, postpartum care, and complication management. Patients with PAH also require disease-specific counseling on contraception and breastfeeding. In this review, we detail the considerations for reproductive planning, pregnancy, and delivery for the multidisciplinary care of a patient with PAH.